ReviewFrontiers in endocrinology2020
Androgen-Regulated Cardiac Metabolism in Aging Men.
Review in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Efficacy and Safety of TESTOPEAKAmerican journal of men's healthTrial
- Secondary Hypogonadism and Effects of Testosterone Replacement Therapy on Cardiovascular Events.The Journal of clinical endocrinology and metabolism · 2026Article
- Non-medical use of exogenous testosterone and anabolic-androgenic substances in young men: health, psychological, and fertility consequences.Frontiers in endocrinology · 2026Review
- Testosterone Therapy in Older Men: Present and Future Considerations.Drugs & aging · 2025Review
- Sex-Specific Antioxidant and Anti-Inflammatory Protective Effects of AMPK in Cardiovascular Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Association between Low Serum Testosterone Levels and All-cause Mortality in Patients With Cardiovascular Disease: A Study Based on the NHANES Database.Cardiovascular toxicology · 2025Article
- Cardiometabolic deaths in black and white men: Tracing the risks from early- to mid-adulthood.Preventive medicine reports · 2025Article
- Association of metabolic score for insulin resistance with incident metabolic syndrome: a cohort study in middle-aged and older adult Chinese population.Frontiers in public health · 2025Article
- Androgen Signaling in Prostate Cancer: When a Friend Turns Foe.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes.World journal of cardiology · 2024Article
- Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice.Current oncology reports · 2023Review
- Evaluation of the Interaction of Sex Hormones and Cardiovascular Function and Health.Current heart failure reports · 2022Review
- Sexual dimorphism in cardiac remodeling: the molecular mechanisms ruled by sex hormones in the heart.Journal of molecular medicine (Berlin, Germany) · 2022Review
- The Interplay of Sex Steroids, the Immune Response, and the Intestinal Microbiota.Trends in microbiology · 2021Review
- Manifestations of gene expression profiles in human right atrial myocardium caused by mechanical stretch.Heart and vessels · 2021Article
- Associations betweenAging · 2021Article
- Sex Differences in Molecular Mechanisms of Cardiovascular Aging.Frontiers in aging · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of cardiovascular mortality is higher in men than in age-matched premenopausal women. Gender differences are linked to circulating sex-related steroid hormone levels and their cardio-specific actions, which are critical factors involved in the prevalence and features of age-associated cardiovascular disease. In women, estrogens have been described as cardioprotective agents, while in men, testosterone is the main sex steroid hormone. The effects of testosterone as a metabolic regulator and cardioprotective agent in aging men are poorly understood. With advancing age, testosterone levels gradually decrease in men, an effect associated with increasing fat mass, decrease in lean body mass, dyslipidemia, insulin resistance and adjustment in energy substrate metabolism. Aging is associated with a decline in metabolism, characterized by modifications in cardiac function, excitation-contraction coupling, and lower efficacy to generate energy. Testosterone deficiency -as found in elderly men- rapidly becomes an epidemic condition, associated with prominent cardiometabolic disorders. Therefore, it is highly probable that senior men showing low testosterone levels will display symptoms of androgen deficiency, presenting an unfavorable metabolic profile and increased cardiovascular risk. Moreover, recent reports establish that testosterone replacement improves cardiomyocyte bioenergetics, increases glucose metabolism and reduces insulin resistance in elderly men. Thus, testosterone-related metabolic signaling and gene expression may constitute relevant therapeutic target for preventing, or treating, age- and gender-related cardiometabolic diseases in men. Here, we will discuss the impact of current evidence showing how cardiac metabolism is regulated by androgen levels in aging men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.